Cooper Companies (the) Stock News

Fifth Third Bancorp increased its holdings in shares of The Cooper Companies, Inc. (NYSE:COO) by 12.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 401 shares of the medical device companys stock after acquiring an additional 45 shares during the quarter. Fifth Third Bancorps []

The Cooper Companies, Inc. (NYSE:COO) Stock analysts at Jefferies Financial Group dropped their Q1 2022 EPS estimates for shares of Cooper Companies in a research note issued on Thursday, December 2nd. Jefferies Financial Group analyst A. Petrone now forecasts that the medical device company will post earnings per share of $3.22 for the quarter, []

The Cooper Companies found using ticker (COO) have now 12 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 560 and 400 calculating the average target price we see 466.75. Now with the previous closing price of 391.56 this would indicate that there is a potential upside of 19.2%. The 50 day MA is 409.88 while the 200 day moving average is 405.59. The company has a market capitalisation of $19,720m. Company Website: https://www.coopercos.com [stock_market_widget type="chart" symbol="COO" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] The Cooper Companies operates as a medical device company worldwide. It operates through two segments, CooperVision and CooperSurgical. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.

Assenagon Asset Management S.A. trimmed its stake in The Cooper Companies, Inc. (NYSE:COO) by 70.5% in the 3rd quarter, HoldingsChannel reports. The firm owned 10,844 shares of the medical device companys stock after selling 25,888 shares during the period. Assenagon Asset Management S.A.s holdings in Cooper Companies were worth $4,482,000 as of its most recent []

Cooper Companies (NYSE:COO) had its target price trimmed by KeyCorp from $465.00 to $459.00 in a report published on Friday, Analyst Price Targets reports. They currently have an overweight rating on the medical device companys stock. KeyCorp also issued estimates for Cooper Companies Q1 2022 earnings at $3.10 EPS, Q2 2022 earnings at $3.56 EPS, [] The post KeyCorp Cuts Cooper Companies (NYSE:COO) Price Target to $459.00 appeared first on ETF Daily News .

The Cooper Companies, Inc. (NYSE:COO) Equities research analysts at Jefferies Financial Group cut their Q1 2022 EPS estimates for shares of Cooper Companies in a report released on Thursday, December 2nd. Jefferies Financial Group analyst A. Petrone now forecasts that the medical device company will post earnings of $3.22 per share for the quarter, []

Robert W. Baird reaffirmed their hold rating on shares of Cooper Companies (NYSE:COO) in a research note released on Friday morning, TipRanks reports. Robert W. Baird currently has a $431.00 price target on the medical device companys stock. COO has been the topic of several other reports. Oppenheimer lifted their target price on shares of []

Cooper Companies (NYSE:COO) had its price target trimmed by KeyCorp from $465.00 to $459.00 in a research note published on Friday, Price Targets.com reports. The brokerage currently has an overweight rating on the medical device companys stock. KeyCorp also issued estimates for Cooper Companies Q1 2022 earnings at $3.10 EPS, Q2 2022 earnings at $3.56 []

Cooper Companies (NYSE:COO) issued an update on its FY22 earnings guidance on Thursday morning. The company provided EPS guidance of $13.60-$14.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $14.49. The company issued revenue guidance of $3.032-$3.090 billion, compared to the consensus revenue estimate of $3.09 billion.Cooper Companies also updated its []

In trading on Friday, the Invesco S&P 500 QVM Multi-factor ETF is outperforming other ETFs, up about 1.1% on the day. Components of that ETF showing particular strength include shares of The Cooper Companies, up about 2.9% and shares of Nucor, up about 2.5% on the day. And underperforming other ETFs today is the ARK [] The post Fridays ETF Movers: QVML, ARKK appeared first on UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News .

Cooper Companies Inc (NYSE: COO ) reported that Q4 sales increased 11% Y/Y to $759.1 million , beating the consensus of $747.85 million. Q4 adjusted EPS of $3.28 increased 4% Y/Y, missing the consensus of $3.37. Adjusted gross margin compressed to 67% from 68% a year ago, driven primarily by currency. Adjusted operating margin was 25%, down from 27% last year, driven … Full story available on Benzinga.com

Cooper Companies Inc (NYSE: COO) reported that Q4 sales increased 11% Y/Y to $759.1 million, beating the consensus of $747.85 million. Q4 adjusted EPS of $3.28 increased 4% Y/Y, missing the consensu

Cooper Companies (NYSE:COO) posted its quarterly earnings results on Thursday. The medical device company reported $3.28 EPS for the quarter, missing the consensus estimate of $3.38 by ($0.10), MarketWatch Earnings reports. The company had revenue of $759.10 million for the quarter, compared to analysts expectations of $748.17 million. Cooper Companies had a net margin of []

Cooper Companies (NYSE:COO) had its price target reduced by equities research analysts at Citigroup from $453.00 to $425.00 in a research report issued on Friday, The Fly reports. The firm presently has a neutral rating on the medical device companys stock. Citigroups price objective suggests a potential upside of 12.45% from the stocks previous close. []

According to the new market research report "Infertility Treatment Market by Product (Equipment, Media, Accessories), Procedure (ART (IVF,ICSI, Surrogate), Insemination, Laparoscopy, Hysteroscopy, Patient Type (Female, Male), End User (Fertility Clinics, Hospitals, Research) - Global Forecast to 2026", published by MarketsandMarkets,